Atomwise
✓ Verified
Healthcare AI
AI drug discovery / small-molecule discovery
Series B
Atomwise is an AI-driven preclinical drug discovery company focused on using its AtomNet deep-learning platform for structure-based virtual screening and small-molecule design. It has historically partnered with pharmaceutical, biotech, academic, and agrochemical organizations to support early-stage discovery, and recent reporting indicates the company has transitioned or rebranded to Numerion Labs around October 2025.
Company Details
- Website
- atomwise.com
- Headquarters
- San Francisco, California, United States
- Founded
- 2012
- Funding
- Approximately $219M
Subscriber Intelligence
- • Deal signal alerts for this company
- • Sentiment & risk scoring
- • Competitive framework analysis
- • Regulatory event monitoring